Display Settings:

Items per page

Results: 6

1.
Figure 6

Figure 6. From: Identification of Phenylbutyrate-Generated Metabolites in Huntington Disease Patients using Parallel LC/EC-array/MS and Off-line Tandem MS.

Structures and fragments of metabolites found in SPB-treated HD patient plasma and urine. Structures and fragments correspond to those listed in Tables 1 and 2.

Erika N. Ebbel, et al. Anal Biochem. ;399(2):152-161.
2.
Figure 2

Figure 2. From: Identification of Phenylbutyrate-Generated Metabolites in Huntington Disease Patients using Parallel LC/EC-array/MS and Off-line Tandem MS.

Flow chart showing the course of samples from initial offline LC-EC-array screening through sample fractionation, parallel LC-EC-array-MS analysis and high resolution and MS/MS characterization.

Erika N. Ebbel, et al. Anal Biochem. ;399(2):152-161.
3.
Figure 3

Figure 3. From: Identification of Phenylbutyrate-Generated Metabolites in Huntington Disease Patients using Parallel LC/EC-array/MS and Off-line Tandem MS.

LC-EC-array chromatograms of the 40% ACN fraction collected from the Diazam C-18 column. Elution of a metabolite of interest is indicated at the retention time of 32 minutes. PB is not EC active.

Erika N. Ebbel, et al. Anal Biochem. ;399(2):152-161.
4.
Figure 1

Figure 1. From: Identification of Phenylbutyrate-Generated Metabolites in Huntington Disease Patients using Parallel LC/EC-array/MS and Off-line Tandem MS.

LC-EC-array/UV/F method showing full 14-channel LC-EC-array/UV/Fluorescence-detected chromatograms of plasma from a patient, taken (A) before treatment and (B) on visit 6 after SPB-treatment. Metabolites of interest (M), phenylacetate (PA) and phenylbutyrate (PB) are labeled in B. This figure was generated directly from the CoulArray software.

Erika N. Ebbel, et al. Anal Biochem. ;399(2):152-161.
5.
Figure 4

Figure 4. From: Identification of Phenylbutyrate-Generated Metabolites in Huntington Disease Patients using Parallel LC/EC-array/MS and Off-line Tandem MS.

(A) QStar Q-o-TOF MS total ion chromatogram of the 40% ACN plasma fraction containing phenylbutyrate (PB) and an unknown SPB metabolite. Other panels show single ion chromatograms of (B) m/z 163, corresponding to the [M-H] of PB, and (C) m/z 117 and (D) m/z 161) which both displayed maxima at the retention time (32 min) of the unknown metabolite.

Erika N. Ebbel, et al. Anal Biochem. ;399(2):152-161.
6.
Figure 5

Figure 5. From: Identification of Phenylbutyrate-Generated Metabolites in Huntington Disease Patients using Parallel LC/EC-array/MS and Off-line Tandem MS.

Orbitrap nanospray MS spectrum of 40% ACN fraction collected from Diazam C-18 column at 32 min. Ions assigned to the unknown SPB metabolite (m/z 161.0613, 117.0713) are circled. The ([M-H]m/z 163.0769) peak indicates presence of a the leading edge of the peak corresponding to the parent drug PB which reached its maximum in the following LC fraction. Inset shows Orbitrap MS/MS spectrum of the unknown metabolite, [M-H]m/z 161.0609. Proposed structures are indicated for the metabolite selected as precursor and its abundant fragment ions.

Erika N. Ebbel, et al. Anal Biochem. ;399(2):152-161.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk